- Trial phase
- Phase 1
- Time to market
- Not applicable; VX-272 is in Phase 1 healthy-volunteer studies and has not yet entered patient trials. If successfully developed, approval would be several years away, and Vertex has said it may select only the best of its multiple next-gen corrector candidates to advance.
- Why 2/10
- No scheduled hard, dated catalyst exists for VX-272 in the next ~12 months. The Phase 1 trial primary completion is March 2027, and even when data emerges, it will be early healthy-volunteer safety/PK data for a single program at a large, diversified biotech company with multiple approved products and a market cap over $100 billion. This drug is not a value driver in its own right at this stage.
VX-272 has no imminent catalyst. The single active Phase 1 trial (NCT07437105) has a primary completion date around March 2027. Vertex is running multiple next-gen correctors (VX-581, VX-272, VX-828) in parallel and has said it expects to advance the best asset into further development. For Vertex shareholders, the more material near-term catalysts are the povetacicept PDUFA (IgA nephropathy) on November 30, 2026, and the inaxaplin pivotal readout in early 2027. VX-272 data, when it comes, will inform whether Vertex has a potential successor to its CF franchise, but Phase 1 healthy-volunteer safety/PK data alone is unlikely to be a stock-moving event for a company of Vertex's size.
Price Chart
Executive Summary
VX-272 is a next-generation "3.0" CFTR corrector in Phase 1 testing for cystic fibrosis, developed by Vertex Pharmaceuticals (VRTX). It is designed to help misfolded CFTR protein reach the cell surface, one of several candidates Vertex is evaluating to potentially improve upon its existing CFTR modulator franchise (TRIKAFTA/ALYFTREK). Vertex began dosing healthy volunteers in mid-2026 and continues to enroll the Phase 1 study as of its Q3 2026 earnings report. The drug is highly early-stage and represents a very small part of Vertex's diversified pipeline; no near-term binary catalyst exists for this specific asset.
How It Works
VX-272 is a small-molecule CFTR corrector, part of Vertex's "3.0" next-generation class. In cystic fibrosis, a genetic mutation causes the CFTR protein to be misfolded so it never reaches the cell surface to regulate salt and water flow. VX-272 acts as a pharmacological chaperone, helping the CFTR protein fold correctly so it can traffic to the cell surface where it can be activated by a potentiator drug. It is designed to be used as part of a combination regimen to improve lung function in people with CF.
Trial Status
One active Phase 1 trial (NCT07437105) is a randomized, double-blind, placebo-controlled dose escalation study evaluating safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272 in combination with deutivacaftor (D-IVA) with or without tezacaftor (TEZ) in healthy subjects. The trial is recruiting with a primary completion date of March 23, 2027. As of Vertex's Q3 2026 earnings release (November 2, 2026), the company confirmed it continues to enroll and dose healthy volunteers with VX-272 and VX-581 and expects to study both correctors in people with CF to establish proof of concept.
The Two-Sided Case
Upcoming Catalysts
- No near-term catalyst specific to VX-272. The Phase 1 trial (NCT07437105) primary completion is estimated around March 2027. Vertex may provide pipeline updates at medical conferences or quarterly earnings calls.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
VERTEX PHARMACEUTICALS INC / MA 8-K VRTX ·Originating report